Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at Leerink Partners

Leerink Partners assumed coverage on shares of Maze Therapeutics (NASDAQ:MAZE) in a report released on Tuesday,Benzinga reports. The brokerage issued an outperform rating and a $28.00 price objective on the stock.

Maze Therapeutics Stock Performance

NASDAQ MAZE opened at $10.57 on Tuesday. Maze Therapeutics has a 1-year low of $10.08 and a 1-year high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.